Pacific EdgeASX:PEB -4.00%42 Altman Z-Score is -0.55 as of Jun. 27, 2026. GuruFocus rates ASX:PEB with a GF Score™ of 42/100 and a GF Value™ of A$0.05 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Pacific Edge ranks worse than 66.18% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Pacific Edge has a Altman Z-Score of -0.55, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Pacific Edge's Altman Z-Score or its related term are showing as below:
During the past 13 years, Pacific Edge's highest Altman Z-Score was 68.08. The lowest was -15.00. And the median was 22.49.
Pacific Edge (ASX:PEB) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Pacific Edge Altman Z-Score Related Terms
Pacific Edge Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Pacific Edge's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:PEB vs TMO, DHR, IDXX: Altman Z-Score Comparison
For the Diagnostics & Research subindustry, Pacific Edge's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacific Edge Altman Z-Score vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Pacific Edge's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Pacific Edge's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Pacific Edge's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.3952
+
1.4
*
-17.7187
+
3.3
*
-2.0315
+
0.6
*
49.7293
+
1.0
*
0.6533
=
-0.55
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Pacific Edge (ASX:PEB) has a Altman Z-Score of -0.55 as of Jun. 27, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Pacific Edge and its competitors. According to the industry distribution chart, Pacific Edge ranks #135 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 66.2%.
Is Pacific Edge's Altman Z-Score too high?
Pacific Edge's current Altman Z-Score is -0.55. Based on the distribution chart, Pacific Edge ranks #135 out of 204 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Pacific Edge has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pacific Edge's Altman Z-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Pacific Edge ranks #135 out of 204 companies for Altman Z-Score. This places Pacific Edge in the lower half of its industry. The industry median Altman Z-Score is 2.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Diagnostics & Research company?
The median Altman Z-Score among Medical Diagnostics & Research companies is 2.40, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Pacific Edge and its competitors. For the Medical Diagnostics & Research industry, the median Altman Z-Score is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacific Edge's current Altman Z-Score is -0.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Edge stock overvalued right now?
Based on GuruFocus' analysis, Pacific Edge (ASX:PEB) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.05, compared to a current price of A$0.24 — trading 380% above its estimated fair value. The current Altman Z-Score is -0.55. Pacific Edge's overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Pacific Edge (ASX:PEB), the current Altman Z-Score is -0.55 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacific Edge (ASX:PEB) Overvalued in 2026?
Based on GuruFocus' analysis, Pacific Edge stock appears to be overvalued.
The current stock price of A$0.24 is trading 380% above its estimated GF Value™ of A$0.05.
GuruFocus considers Pacific Edge to be Significantly Overvalued.
Key valuation signals for ASX:PEB:
Altman Z-Score: -0.55
GF Value™: A$0.05 vs. price of A$0.24 (380% above fair value)
No single metric tells the full story. See the ASX:PEB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacific Edge Ltd is a New Zealand-based company involved in researching, developing, and commercialising new diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. It operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses internationally; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, which generates maximum revenue, New Zealand, and the Rest of the World.
42GF Score
Get the complete analysis for ASX:PEB
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PEB has been successfully added to your 
